AstraZeneca and Takeda Strike $400 Million Development Deal for Investigational Parkinson’s Agent
AstraZeneca and Takeda Pharmaceutical Company Limited will jointly develop and commercialize an investigational alpha-synuclein antibody currently in development for the treatment of Parkinson’s disease (PD) known as MEDI1341. Differentiated by its high affinity, high selectivity, and reduced effector function (lower interaction with the immune system), MEDI1341 has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies, according to the two companies.
Under the terms of the agreement, AstraZeneca will lead Phase I development while Takeda will lead future clinical development activities. Takeda will pay AstraZeneca up to $400 million, including initial revenue in 2017 and development and sales milestones thereafter.
MEDI1341 is due to enter Phase I clinical trials later this year.